ALCMI, Champions Oncology, and ROS1ders to Launch Clinical Study

Posted by ALCF Staff on August 15th, 2017

The Addario Lung Cancer Medical Institute (ALCMI), and Champions Oncology (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, announce a research collaboration and initiation of the ALCMI-006 study, which was developed and will be conducted by ALCMI and its consortium of leading U.S. and international oncology centers. This global study will focus on patients whose tumors contain a ROS1 gene rearrangement, with the goal to develop new models to study this uncommon yet clinically important genotype of cancer.

Click here to read the full press release

Comments are closed.